Brentuximab vedotin, an antibody–drug conjugate comprised of anti-CD30 monoclonal antibody conjugated to the anti-microtubule agent monomethyl auristatin E, has shown efficacy for relapsed/refractory ALCL but is also not thought to cross the BBB [1, 42, 43]. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.